DAWN
NASDAQ · Biotechnology
Day One Biopharmaceuticals I
$21.44
+0.05 (+0.23%)
Open$21.36
Previous Close$21.39
Day High$21.44
Day Low$21.30
52W High$13.20
52W Low$5.64
Volume—
Avg Volume3.20M
Market Cap1.35B
P/E Ratio—
EPS$-1.04
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+162.5% upside
Current
$21.44
$21.44
Target
$56.28
$56.28
$41.40
$56.28 avg
$65.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 176.22M | 322.81M | 330.87M |
| Net Income | -119,557,993 | -68,873,512 | -86,473,457 |
| Profit Margin | -67.9% | -21.3% | -26.1% |
| EBITDA | -141,931,284 | -92,549,420 | -89,278,899 |
| Free Cash Flow | — | -81,242,335 | -91,466,852 |
| Rev Growth | — | +3.3% | -3.7% |
| Debt/Equity | — | 0.57 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |